Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to NeoGenomics, Inc. (NASDAQ: NEO) SEC filings, offering a regulatory view of the company’s activities as a public cancer diagnostics business. NeoGenomics is a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol NEO, as disclosed in its Form 8-K filings.
Investors can review current reports on Form 8-K, which NeoGenomics uses to furnish quarterly financial results, preliminary revenue updates, and information about board and executive changes. Recent 8-K filings have reported results for fiscal quarters, described financial metrics such as revenue and operating expenses, and documented director appointments and resignations.
Through this page, users can also monitor quarterly and annual reports (Forms 10-Q and 10-K when available) that typically include detailed discussions of the company’s oncology diagnostics operations, risk factors, and financial statements. These filings complement the company’s news releases describing clinical test volumes, next-generation sequencing contributions, and research and development spending.
For those tracking governance and corporate actions, the SEC filings detail matters such as board composition and compensation arrangements for directors, as reflected in 8-K disclosures about board changes. Filings related to financial results often reference non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit Margin, with reconciliations and definitions included in the attached press releases.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes from prior periods, and make it easier to locate items related to revenue trends, operating performance, and governance updates. Real-time updates from EDGAR help ensure that new NeoGenomics filings, including any future Forms 10-K, 10-Q, or Form 4 insider transaction reports, are quickly reflected and summarized for NEO investors and researchers.
NeoGenomics, Inc. reported fourth-quarter and full-year 2025 results showing solid revenue growth but continued net losses. Fourth-quarter revenue rose 11% to $190.2 million, with full-year revenue up 10% to $727.3 million, driven by higher test volumes and a shift toward higher value oncology diagnostics.
Fourth-quarter net loss improved to $9.9 million from $15.3 million, while full-year net loss widened to $108.0 million due to items such as impairment and litigation costs. Non-GAAP adjusted EBITDA was positive $13.4 million in Q4 and $43.4 million for 2025, both modestly higher than 2024.
The company highlighted strong growth in next‑generation sequencing, progress on its RaDaR ST minimal residual disease assay, and a successful resolution of RaDaR ST patent litigation. For 2026, NeoGenomics guides revenue to $793–801 million, a smaller GAAP net loss of $50–63 million, and adjusted EBITDA of $55–57 million.
NeoGenomics Inc. President & Chief Operating Officer Stone Warren reported a sale of company stock. On January 20, 2026, he sold 22,128 shares of common stock at a price of $12.5037 per share, leaving him with 121,631 common shares owned directly.
The filing also lists his existing equity awards, including stock options and restricted and performance stock units granted between 2022 and 2025. These include options to buy 166,113 shares at $11.21 exercisable until December 1, 2029, and additional option grants such as 143,266 options and 94,518 options that vest in stages over two years. He also holds sizable restricted stock unit and performance stock unit awards, such as 84,317, 59,382, and 52,687 share-equivalent RSU positions, with vesting tied to continued service and, for performance units, to share price and revenue growth goals. Some options were granted at a premium exercise price set at 110% of the stock’s closing price on specified grant dates.
A holder of NEO common stock has filed a notice under Rule 144 to sell 22,128 shares through Morgan Stanley Smith Barney LLC on the NASDAQ. The filing lists an aggregate market value of about $283,017.12 for the planned sale and identifies that the class of securities is common stock. The notice states that 129,387,801 shares of this class were outstanding at the time of the filing, which serves as a baseline figure, not the amount being sold. The shares to be sold were acquired as restricted stock units from the issuer on January 13, 2026, with the sale expected to occur around January 20, 2026.
NeoGenomics (NEO) President & Chief Operating Officer Warren Stone reported equity activity on January 13, 2026. He acquired 59,382 shares of common stock through the vesting of restricted stock units at an effective price of $0 per share, then disposed of 15,127 shares in a transaction tied to tax withholding obligations. Following these transactions, he directly beneficially owned 143,759 shares of NeoGenomics common stock.
The filing also lists substantial outstanding equity awards, including stock options, restricted stock units, and performance stock units covering multiple future vesting and expiration dates, reflecting a significant portion of his compensation in equity incentives.
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity transactions tied to previously granted awards. On January 13, 2026, 59,382 shares of common stock were acquired at $0 per share under transaction code M, reflecting the release of vested restricted stock units. In connection with this vesting, 15,145 shares were disposed of under transaction code F at $0 to cover tax withholding obligations.
Following these transactions, Ms. Olivo directly owned 75,320 shares of NeoGenomics common stock. She also held a range of equity awards, including stock options with various exercise prices and expiration dates, as well as restricted stock units and performance stock units that convert into common stock upon vesting.
NeoGenomics reported select preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, while emphasizing that these figures are based on management estimates and may change after the year-end audit.
The company also outlined a planned finance leadership transition. Chief Financial Officer Jeffrey S. Sherman notified the board of his intention to retire and will move to Executive Vice President, Finance on March 2, 2026, serve in that role until April 14, 2026, and then act as a special advisor through April 2028. Abhishek Jain has been appointed Executive Vice President, Finance and is expected to become Chief Financial Officer on March 2, 2026. His compensation includes a $520,000 annual base salary, a target annual bonus equal to 60% of salary, and an initial equity award valued at $2,750,000 split evenly between three-year vesting restricted stock units and premium-priced stock options.
NeoGenomics, Inc. reported Q3 2025 results with net revenue of $187.8 million, up from $167.8 million a year ago, as testing volumes and payer mix lifted sales. Gross profit was $80.4 million. The company posted a net loss of $27.1 million (basic and diluted loss per share of $0.21), reflecting higher operating expenses and impairment charges.
Operating loss was $27.0 million, including a $7.1 million impairment tied to a business classified as held for sale. Year to date, net revenue reached $537.2 million and net loss was $98.1 million. Cash and cash equivalents were $164.1 million as of September 30, 2025, after repaying $201.3 million of 2025 convertible notes and $1.3 million of interest in May. Operating cash flow was $3.9 million for the first nine months.
The company closed the Pathline acquisition for $8.5 million; Pathline contributed $4.6 million of revenue in Q3 and recorded a net loss of $2.2 million. Assets held for sale related to Trapelo totaled $2.1 million, and total impairment for the disposal group was $15.3 million year to date. As of October 24, 2025, shares outstanding were 129,387,801.
NeoGenomics, Inc. (NEO) announced that it furnished a press release reporting results for its third fiscal quarter of 2025. The press release, dated October 28, 2025, is included as Exhibit 99.1.
The company states this information is furnished and is not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in other filings.
NeoGenomics (NEO) executive Alicia C. Olivo (EVP, GC & Business Development) reported an open-market sale of common stock. On 10/16/2025, she sold 4,918 shares at $10.00 per share under a Rule 10b5-1 trading plan. Following this transaction, she beneficially owns 43,022 common shares directly.
Her equity awards include multiple grants shown in the filing, such as stock options with exercise prices ranging from $9.45 to $48.99, and time- and performance-based stock units, including 107,450 options with a $13.05 exercise price and 63,238 restricted stock units. The filing notes standard vesting schedules and that once vested, shares of common stock are not subject to expiration.
Alicia C. Olivo, EVP, General Counsel & Business Development of NeoGenomics, reported a Form 4 reflecting a tax-related surrender and extensive outstanding equity awards. On 09/01/2025 she surrendered 1,666 shares to NeoGenomics to satisfy tax withholding upon the vesting of restricted stock, leaving 47,940 shares of common stock beneficially owned. The filing lists multiple stock options, restricted stock units (RSUs) and performance stock units (PSUs) across grants from 2019 through 2025, including large awards on 02/21/2025 of 107,450 options and 63,238 RSUs. Several PSUs have maximum payout caps (e.g., 19,508 target with 29,262 max; 25,330 target with 37,996 max) tied to share-price and revenue goals. Many options vest ratably over 3–4 years and, once vested, shares do not expire.